Sugi Predict

Sugi Predict / Compounds / Ufenamate

Ufenamate

Ufenamate

SCHEMBL29376700

CCCCOC(=O)c1ccccc1Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.72
▸ CYP2C19 P33261 2/20 0.72
▸ LMNA P02545 1/20 0.72
▸ CYP2C9 P11712 1/20 0.72
▸ YAP1 P46937 1/20 0.60
▸ TEAD4 Q15561 1/20 0.60
▸ TEAD2 Q15562 1/20 0.60
▸ RXFP1 Q9HBX9 8/20 0.59
▸ TSHR P16473 2/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ AKR1C3 P42330 2/20 0.51
▸ AKR1C2 P52895 2/20 0.51
▸ SIRT2 Q8IXJ6 1/20 0.51
▸ MPO P05164 3/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ufenamate SCHEMBL36095 1.00 CYP1A2 (0.72) CYP1A2CYP2C19LMNACYP2C9YAP1
SCHEMBL10597386 0.89 LMNA (0.71) CYP1A2CYP2C19LMNACYP2C9YAP1
SCHEMBL28322767 0.87 TSHR (0.56) CYP1A2CYP2C19LMNACYP2C9TSHR
SCHEMBL12715082 0.87 LMNA (0.91) CYP1A2CYP2C19LMNACYP2C9YAP1
SCHEMBL11579676 0.87 LMNA (0.67) CYP1A2CYP2C19LMNACYP2C9YAP1
SCHEMBL4563521 0.86 LMNA (0.68) CYP1A2CYP2C19LMNACYP2C9YAP1
SCHEMBL3812938 0.86 LMNA (0.70) CYP1A2CYP2C19LMNACYP2C9YAP1
Etofenamate SCHEMBL25152 0.83 LMNA (1.00) CYP1A2CYP2C19LMNACYP2C9YAP1
SCHEMBL20820718 0.83 LMNA (0.64) CYP1A2CYP2C19LMNACYP2C9YAP1
Acetic Acid SCHEMBL28343495 0.83 LMNA (0.64) CYP1A2CYP2C19LMNACYP2C9YAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117782740-B Sample treatment fluid for centrifugal microfluidic disc type biochemical analysis chip 阿里生物技术泰州有限公司 2025-03-25 — — CN claimed
CN-117782740-A Sample treatment fluid for centrifugal microfluidic disc type biochemical analysis chip 阿里生物技术泰州有限公司 2024-03-29 — — CN claimed
CN-115721720-A Application of KRAS inhibitor and AKR inhibitor in combination in resisting tumor cell drug resistance 北京大学 2023-03-03 — — CN claimed
EP-4748383-A1 OPHTHALMIC COMPOSITION Rohto Pharmaceutical Co., Ltd. (JP) 2026-05-27 — — EP disclosed
US-12600728-B2 Interleukin-17 inhibitors NOVARTIS AG (CH) 2026-04-14 — — US disclosed
US-20250276957-A1 CRYSTALLINE FORMS OF AN IL-17 INHIBITOR CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, CO., LTD. (CN) 2025-09-04 — — US disclosed
US-20250270188-A1 NLRP3 INFLAMMASOME INHIBITORS NOVARTIS AG (CH) 2025-08-28 — — US disclosed
US-12378222-B2 NLRP3 inflammasome inhibitors NOVARTIS AG (CH) 2025-08-05 — — US disclosed
US-20250228887-A1 OPHTHALMIC COMPOSITION ROHTO PHARMACEUTICAL CO., LTD. (JP) 2025-07-17 — — US disclosed
EP-4577550-A1 NOVEL NLRP3 INFLAMMASOME INHIBITORS Hangzhou Highlightll Pharmaceutical Co., Ltd. (CN) 2025-07-02 — — EP disclosed
US-20250206742-A1 NLRP3 INFLAMMASOME INHIBITORS HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD (CN) 2025-06-26 — — US disclosed
WO-2022095816-A1 TERNARY HERBICIDAL COMPOSITION COMPRISING CARBOXYLIC ACID DERIVATIVE-SUBSTITUTED OXYIMINOARYL COMPOUND AND USE THEREOF 青岛清原化合物有限公司 2022-05-12 — — WO disclosed
WO-2022091056-A1 INTERLEUKIN-17 INHIBITORS NOVARTIS AG (CH) 2022-05-05 — — WO disclosed
US-11311423-B2 Facial patch NICHIBAN CO., LTD. (JP) 2022-04-26 — — US disclosed
US-20220105237-A1 SKIN COMPOSITION MARUHO CO., LTD. (JP) 2022-04-07 — — US disclosed
WO-2022068377-A1 BINARY HERBICIDAL COMPOSITION AND USE THEREOF 青岛清原化合物有限公司 2022-04-07 — — WO disclosed
EP-3969441-A1 NLRP3 INFLAMMASOME INHIBITORS Novartis AG (CH) 2022-03-23 — — EP disclosed
CN-114126574-A External preparation for skin 花王株式会社 2022-03-01 — — CN disclosed
US-11254653-B2 NLRP3 inflammasome inhibitors NOVARTIS AG (CH) 2022-02-22 — — US disclosed
CN-114014760-A Method for synthesizing 3-amino trifluoromethyl benzene by using vortex reactor 南通海晴医药科技有限公司 2022-02-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206742-A1 NLRP3 INFLAMMASOME INHIBITORS NLRP3, NLRP1, NOD1 CYP1A2 1483/4885CYP2C19 2369/4885LMNA 682/4885
US-20250276957-A1 CRYSTALLINE FORMS OF AN IL-17 INHIBITOR IL17A, IL2, IL23R CYP1A2 565/4885CYP2C19 226/4885LMNA 4162/4885
US-11254653-B2 NLRP3 inflammasome inhibitors NLRP3, NLRP1, NOD1 CYP1A2 839/4885CYP2C19 1403/4885LMNA 986/4885
US-12378222-B2 NLRP3 inflammasome inhibitors NLRP3, NLRP1, NOD1 CYP1A2 692/4885CYP2C19 1288/4885LMNA 1169/4885
US-20250270188-A1 NLRP3 INFLAMMASOME INHIBITORS NLRP3, NLRP1, NOD1 CYP1A2 839/4885CYP2C19 1403/4885LMNA 986/4885
US-12600728-B2 Interleukin-17 inhibitors IL17A, IL2, IL1B CYP1A2 416/4885CYP2C19 159/4885LMNA 3977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback